Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
Status:
Withdrawn
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized clinical study with two stages to assess the maximum
tolerated dose (MTD), efficacy, and safety of selinexor, lenalidomide, and dexamethasone
(SLd) in patients with relapsed/refractory (RR) multiple myeloma (MM). The stages are dose
escalation (Phase 1) and expansion (Phase 2).